GleamWall
中文EN

BGLC BioNexus Gene Lab Corp

Services-Medical Laboratories · Nasdaq · SEC CIK 1737523 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY-67.3%
TTM net income YoY12.2%
TTM EPS YoY-27.7%
Revenue 3-yr CAGR-32.9%
Net income 3-yr CAGR—

Margins

Gross margin12.3%
Operating margin-81.8%
Net margin-82.4%
FCF margin-27.3%
EBITDA margin-78.2%

Returns

ROE-33.7%
ROA-28.4%
ROIC (approx.)-32.3%
Asset turnover0.34x

Leverage & solvency

Liabilities / assets10.9%
Debt / equity0.00x
Current ratio6.08x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.33x
Accruals ratio-19.1%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-312024Q32024-09-30
Income statement
Revenue$76,156$22,842$483,760$2.54M$2.26M$2.14M$2.52M$2.63M
Cost of revenue$63,174$23,632$487,743$2.17M$1.89M$1.79M$2.21M$2.30M
Gross profit$12,982-$790-$3,983$377,685$368,022$343,493$309,234$326,536
R&D expense$13,671$14,487$11,098$14,876$12,557$12,139$17,396$10,442
SG&A expense$298,526$327,669$181,095$445,691$516,790$391,876$165,932$792,413
Operating income-$282,396-$540,490-$1.03M-$702,509-$611,293-$618,418-$416,220-$1.34M
Interest expense———————$6,193
Pretax income-$286,451-$543,575-$1.04M-$708,991-$616,172-$623,327-$422,032-$1.34M
Income tax$0$0$0$0$0$0-$80,701$1,555
Net income-$286,451-$543,575-$1.04M-$708,991-$616,172-$623,327-$348,319-$1.35M
EBITDA-$254,331-$512,197-$1.00M-$673,508-$583,493-$591,776-$386,671-$1.26M
EPS (diluted)-0.12-0.23—-0.40-0.34-0.35—-0.75
Weighted avg. shares (diluted)2.42M2.42M—1.80M1.80M1.80M—1.80M
Banking
Net interest income———————$2,429
Balance sheet
Cash & equivalents$1.23M$1.34M$2.38M$1.15M$1.54M$2.09M$2.89M$4.14M
Receivables$15,544$79,860$505,885$1.52M$1.85M—$1.38M—
Inventory$652,892$667,154$676,703$1.01M$1.22M$1.18M$1.39M$1.39M
Current assets$4.94M$5.20M$5.45M$5.63M$6.38M$6.54M$7.43M$7.04M
PP&E, net$1.54M$1.58M$1.60M$1.57M$1.59M$1.52M$1.52M$1.73M
Total assets$8.73M$9.04M$9.25M$7.62M$9.42M$9.48M$10.43M$11.00M
Current liabilities$812,938$796,470$520,957$678,023$1.76M$1.56M$1.95M$1.41M
Total liabilities$947,981$946,877$637,856$804,966$1.90M$1.71M$2.11M$1.61M
Shareholders' equity$7.78M$8.09M$8.61M$6.82M$7.52M$7.77M$8.32M$9.39M
Shares outstanding2.42M2.42M2.42M1.80M1.80M17.97M1.80M17.97M
Cash flow statement
Operating cash flow-$422,491-$147,671$961,062-$1.24M-$737,907-$824,072$219,203-$1.60M
Capital expenditure$250$325$977$5,483$21,459$9,052$4,022$199,189
Free cash flow-$422,741-$147,996$960,085-$1.24M-$759,366-$833,124$215,181-$1.80M
Investing cash flow$416,140-$13,988-$5,717$994,646-$28,532-$15,646$494,158-$203,160
Financing cash flow$13,607$59,709$266,544$34,187-$1,030-$860-$142,387-$55,982
Depreciation & amortization$28,065$28,293$28,430$29,001$27,800$26,642$29,549$74,611
Stock-based compensation——$794,770———$0—

Free plan shows the latest 8 periods; Pro shows all 34 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.